Pioneering Off-the-Shelf CAR-T Therapies for T-Cell Leukemia
Founded in 2018 by scientists from RiverVest and WashU Medicine, Wugen is a clinical-stage biotech focused on developing next-generation, off-the-shelf CAR-T therapies for hematological malignancies. The company’s lead program, WU-CART-007, is engineered to treat T-cell acute lymphoblastic leukemia (T-ALL), a disease affecting children, adolescents, and adults. By combining cutting-edge science with scalable cell therapy platforms, Wugen aims to transform outcomes for patients with limited treatment options.
Wugen Highlights
Since its inception, Wugen has achieved several key milestones in advancing CAR-T therapy:
- Innovative Technology Licensing: Wugen licensed multiple CAR-T and natural killer (NK) technologies from WashU Medicine, forming the scientific foundation for its proprietary therapies.
- Capital Growth: The company has raised over $300M from venture and crossover investors, fueling R&D, clinical development, and infrastructure expansion.
- State-of-the-Art Facilities: Wugen built a standalone facility in the Cortex Innovation District, providing the space and capabilities to support rapid growth and clinical manufacturing.
Clinical Progress: Wugen completed a Phase 1/2 clinical trial of WU-CART-007, demonstrating safety and evidence of anti-leukemic activity in heavily pretreated patients. Remarkably, 91% of patients receiving WU-CART-007 responded to treatment (Ghobadi et al., Blood, 2025). The company recently dosed the first patients in a pivotal Phase 2 trial, moving closer to potential approval as the first allogeneic CAR-T cell therapy for T-cell leukemia.
BioGenerator’s Role in Wugen’s Early Growth
BioGenerator played a foundational role in Wugen’s launch and early expansion. The organization invested $1M in Wugen’s initial financing and supported early talent recruitment, including Mark Lewis, a BioGenerator VC Fellow who became one of Wugen’s first employees and now serves as VP of Finance and Operations.
In addition to funding and human capital, BioGenerator built dedicated laboratory and office space within the BioGenerator Labs, enabling Wugen to scale rapidly to more than 40 employees before moving into its standalone facility. This combination of capital, space, and strategic guidance laid the groundwork for Wugen’s growth into a clinical-stage biotech poised to transform T-cell leukemia treatment.
“We are committed to advancing our CAR-T therapy for T-cell leukemia, WU-CART-007, through to commercialization, ensuring it benefits as many patients as possible.”
Matt Cooper, PhD, Co-founder and Chief Scientific Officer, Wugen Inc.